UNSPSC 51111642: Irinotecan

This classification denotes a camptothecin analogue with the molecular formula C33H38N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7673326042, chemically known as irinotecan, cpt-11 but generally known as irinotecan, which bears US NIH Compound Identifier 60838. European Medicines Agency schedules Irinotecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08295MIG.

UNSPSC 51111642 Irinotecan is a Commodity code for a chemotherapy drug supplied to state and local health systems, correctional facilities, and safety-net providers. State and local governments procure irinotecan — a topoisomerase I inhibitor used in colorectal, lung, and gastric cancer treatment — as part of routine pharmaceutical inventory for oncology departments, inpatient units, and specialty clinics. The drug is typically sourced through group purchasing agreements, state pharmaceutical contracts, or competitive bid processes that aggregate demand across multiple facilities within a jurisdiction or region.

The source provided does not identify recent state or local contract opportunities, issuing bodies, geographic activity, or response dates for irinotecan procurement under this code. Without posted solicitations or awarded contracts in the available data, no representative opportunities can be named or analyzed for timing, volume, or contracting approach.